1. Introduction {#sec1}
===============

Maintenance of glucose homeostasis is fundamental to mammalian survival. Multiple molecular mechanisms driven by endocrine hormones contribute to appropriate timing of glucose liberation and synthesis when food is scarce and glucose uptake and storage when food is plentiful. The liver is the primary source of endogenous glucose production during fasting, when the catabolic hormone glucagon stimulates hepatic glycogen breakdown as well as gluconeogenesis by activating transcription of rate-limiting gluconeogenic enzymes and transcriptional regulators including *Pepck, G6pase* and *Pgc1α* [@bib1]. After feeding, insulin stimulates glucose uptake and storage primarily in skeletal muscle and suppresses hepatic glucose production [@bib2]. When animals become obese and insulin resistant, blood glucose becomes poorly controlled due to the combination of excess hepatic glucagon action and multi-tissue insulin resistance. The increasing prevalence of pre-diabetes and type 2 diabetes has resulted in an urgent need to identify new therapeutic strategies to improve insulin sensitivity.

The cAMP response element binding protein (CREB) directly stimulates expression of hepatic gluconeogenesis genes and is required to maintain fasting blood glucose levels in mice [@bib3]. cAMP-regulated transcriptional co-activator 2 (CRTC2) is a key component of activated CREB complexes on *Pepck, G6pase* and *Pgc1α* promoters and contributes to the hepatic fasting gluconeogenic response [@bib4], [@bib5], [@bib6], [@bib7]. In insulin resistant rodents, in which hepatic CREB/CRTC activity becomes elevated [@bib8], acute knock-down of CREB or CRTC2 in liver normalizes blood glucose [@bib9], [@bib10]. Global CRTC2 knockout mice fed high fat diet have improved insulin sensitivity, possibly secondary to reduced hepatic glucose production [@bib6]. CRTC subcellular localization and subsequently activity are regulated by AMPK-related kinases. In particular, salt-inducible kinases (SIK1-3) directly phosphorylate CRTCs on 14-3-3 binding sites and thereby cause cytosolic retention [@bib11]. In addition to SIKs, MARK2 and AMPK itself also phosphorylate CRTCs on the same sites [@bib4], [@bib12], [@bib13].

Among CRTC kinases, SIK1 is unique in that it is a direct CREB target gene in liver, skeletal muscle, adrenal cortical cells and neurons [@bib14]. SIK1 is therefore thought to constitute an intrinsic inhibitory feedback circuit to efficiently stop CREB target gene expression after the original stimulus ends, such as after re-feeding when glucagon and catecholamine signaling decline. Indeed, adenoviral knockdown of *Sik1* in liver was sufficient to increase CREB activity and blood glucose levels [@bib4]. However, in obese *db/db* mice, *Sik1* mRNA increases in several tissues including liver [@bib15], yet hepatic CRTC2 activity remains abnormally high [@bib8]. It is therefore clear that, at least in some settings, SIK1 is not required to regulate CRTC2. Indeed, a recently reported global SIK1 knockout mouse strain did not exhibit hyperglycemia but rather improved insulin secretion. SIK1 was found to catalyze activating phosphorylation of PDE4D in beta cells; SIK1 knockout increased intracellular cAMP in beta cells and potentiated glucose-stimulated insulin secretion [@bib16]. However, these studies were conducted on global SIK1 knockout mice, so tissue specific effects may not have been apparent.

*Sik1* is broadly expressed, indicating that it may have multiple roles in physiology. We previously showed that in skeletal muscle, SIK1 maintains MEF2 activity by catalyzing inhibitory phosphorylation on class II HDAC kinases [@bib17]. This pathway is also operant during myoblast differentiation, when SIK1 accumulates by transcriptional and post-translational mechanisms [@bib18]. In adult muscle, *Sik1* expression is acutely induced by strenuous exercise training [@bib19], as well as by over-nutrition (obese *db/db*) [@bib15] and acute muscle injury [@bib20]. However, nothing is known about how skeletal muscle SIK1 contributes to metabolic homeostasis or how SIK1 may exert distinct functions in other metabolic tissues because to date no conditional *Sik1* knockout model has been available.

To analyze cell-autonomous and cell non-autonomous roles of *Sik1* in glucose homeostasis *in vivo*, we generated conditional *Sik1* knockout mice lacking exons encoding the catalytic kinase domain. Here we show that genetic deletion of *Sik1* in all tissues does not result in hyperglycemia or increased hepatic gluconeogenesis *in vivo,* but rather a marked improvement in glucose tolerance, peripheral insulin sensitivity and skeletal muscle glucose uptake on high fat diet. Liver *Sik1* deletion alone did not de-repress gluconeogenesis, despite the fact that isolated hepatocytes lacking SIK1 showed elevated transcription of gluconeogenic genes and glucose output. *Sik1* mRNA is elevated in skeletal muscle of HFD-fed mice, and skeletal muscle-specific SIK1-KO mice, but not liver or adipose tissue SIK1-KO, have enhanced insulin sensitivity after HFD feeding. We therefore identify skeletal muscle as the site of SIK1 action required for development of full insulin resistance in obesity and provide the first evidence that SIK1 is a promising therapeutic target to improve peripheral insulin sensitivity in obese individuals.

2. Methods {#sec2}
==========

2.1. Mice {#sec2.1}
---------

Generation of *Sik1* conditional KO mice (MGI accession nos. [5648544](mgi:5648544){#intref0010}, [5648545](mgi:5648545){#intref0015}, [5648836](mgi:5648836){#intref0020}) and crosses to generate tissue-specific lines are described in [Supplementary Material and Supplementary Table T1](#appsec2){ref-type="sec"}. Male animals aged 8--30 weeks were used for metabolism studies. Knockout mice were backcrossed 3--7 generations to C57Bl6/J, at which point they were 94--99% C57Bl6/J based on SNP mapping (Charles River MaxBax Mouse 384 SNP panel). Animals were housed at 22 °C in individually ventilated cages with a 12 h light/dark cycle (9 AM--9PM) with free access to water and irradiated chow diet (LabDiet 5053). Animals were fasted in cages with synthetic bedding at 5 PM (overnight) or 9 AM (6 h). *Ad lib* blood samples were collected between 9 AM and 2 PM from conscious mice by tail or sub-mandibular bleed. Blood glucose was tested with a glucometer (OneTouch Ultra). Animals were fed 60% high fat diet (HFD, TestDiet 58G9) for up to 20 weeks. Glucose and pyruvate tolerance tests (GTT, PTT) were performed on overnight fasted mice, 1−1.5 g/kg glucose or 2 g/kg sodium pyruvate IP. For insulin tolerance tests (ITT), mice were fasted for 6 h followed by IP insulin (HumulinR^®^) injection (0.75--1 U/kg). For acute insulin signaling studies, mice were fasted for 4--6 h, injected IP with 0.75 (chow diet) or 1.5 (HFD) U/kg insulin and euthanized 15 min later. Recombinant AAV (AAV2/8-TBG-GFP or AAV2/8-TBG-Cre, 1.5 × 10^11^ vector genomes per animal, Penn Vector Core) was injected into the tail vein of 8--10 week old mice ≥7 days prior to testing. Body composition was determined by ECHO-MRI. Hyperinsulinemic-euglycemic clamps were performed in a similar manner to prior studies [@bib21] on overnight fasted, unrestrained HFD-fed mice using a continuous infusion of regular insulin (Humulin R, 8 mU/min/kg body weight). Cold glucose (25%) was infused at a variable rate throughout the experiment to clamp blood glucose levels between 100 and 140 mg/dL (see also Supplementary Material). HPLC purified \[3-^3^H\]glucose was infused as previously described to determine glucose fluxes [@bib21]. For glucose uptake during clamps, a 10 μCi bolus of \[1-^14^C\]2-deoxyglucose was injected 45 min before the end of the clamp, with blood samples collected at intervals over 45 min. Skeletal muscle glucose uptake during the clamp was calculated from the plasma \[^14^C\]2-deoxyglucose profile fitted with a double exponential curve and the tissue content of \[^14^C\]2-deoxyglucose-6-phosphate. Alternatively, ^18^F-labelled 2-deoxyglucose (Cyclotope, Houston TX) was injected (0.1 nmol, ∼0.4 mg/kg) into the tail vein of anesthetized mice fed HFD for 18 weeks followed immediately by an IP injection of insulin (0.75 mg/kg). 30 min later, animals were euthanized and tissues were collected for ^18^F quantification in a gamma counter, with data reported as % injected dose/g tissue weight.

2.2. Primary cells {#sec2.2}
------------------

Primary hepatocytes were prepared from anesthetized mice by hepatic perfusion with type IV collagenase (Sigma, C5138, 120 U/mL) as described [@bib22]. Where indicated, hepatocytes were infected with 1--10 PFU recombinant adenovirus encoding unspecific or *Sik1*-selective shRNA [@bib4] or transfected (Lipofectamine 2000, Life Technologies) with 5 nM control or *Sik1*-selective siRNA ([Supplementary Table T1](#appsec2){ref-type="sec"}) 24 h prior to analysis. Cells were treated with glucagon (100 nM) or FSK/IBMX (forskolin 10 μM/isobutylmethylxanthine 18 μM, Sigma). For cycloheximide (CHX) chase assays, cells were washed in chase medium containing CHX (50 μg/mL) twice, then incubated in fresh medium containing CHX. MG-132 (10 μM, Cayman) was added 30 min prior to the first wash and maintained in the chase medium. Glucose output assays were performed on hepatocytes 24 h after isolation or 24--48 h after transfection as described [@bib22]. Mature brown adipocytes were partially purified by digestion of fat pads from adult mice with type I collagenase (Worthington, 1500 U/mL) and collection of the floating adipocytes for immediate nucleic acid purification.

2.3. Nucleic acid analysis {#sec2.3}
--------------------------

Genomic DNA was purified by phenol: chloroform extraction and isopropanol precipitation. Total RNA was prepared using commercial kits with on-column DNase I digestion (5 Prime, Zymo). cDNA was prepared using MMLV reverse transcriptase (NEB ProtoScript II) with oligo-dT primers. Quantitative real-time PCR (qPCR) was performed on a Roche LC480 with Roche SYBR Master mix as described [@bib22] and primers in [Supplementary Table T1](#appsec2){ref-type="sec"}.

2.4. Protein analysis {#sec2.4}
---------------------

Total protein extracts from cells were prepared in RIPA buffer [@bib22] containing 0.1--2% SDS. Frozen tissues were pulverized in LN~2~ and homogenized in RIPA buffer using a rotor-stator homogenizer. Samples were sonicated and centrifuged (13,000 ×*g*, 15 min, 4 °C) prior to BCA assay and either immunoprecipitation (IP) or addition of 6X Laemmli sample buffer (LSB), boiling and SDS-PAGE resolution. SIK1 was detected on western blots with custom affinity purified anti-SIK1 antibodies: 7129 \[GST-SIK1(343-776) [@bib18]\] or YZ5111, YZ51112 \[custom rabbit polyclonal antibody (YenZym Antibodies, LLC) to GST-rSIK1(350-550), [Supplementary Figure S1 A,B](#appsec2){ref-type="sec"}\]. Commercial antibodies and IP methodology are described in [Supplementary Material](#appsec2){ref-type="sec"}.

2.5. Metabolites {#sec2.5}
----------------

Plasma insulin levels were measured by immunoassay (Millipore Milliplex Mouse Metabolic Hormone panel MMHMAG-44 or Mercodia Mouse Insulin Elisa). For hepatic metabolites, tissue extracts were prepared from 30 mg of liver tissue in ice-cold RIPA buffer. For lipid extraction, 200 μL of homogenate was extracted in 800 μL of chloroform: methanol (2:1). The organic phase was collected, dried and re-suspended in 2% Triton X-100 (v/v) in chloroform. Glycogen was quantified as described [@bib22]. Other analytes were quantified using commercial kits: Serum Triglyceride Determination Kit (Sigma), Free Fatty Acid Quantitation Kit (Sigma), Amplex^®^ Red Cholesterol Assay Kit (Life Technologies), Adiponectin (mouse) total and high molecular weight ELISA (ALPCO).

2.6. Statistics {#sec2.6}
---------------

Statistical analysis was two-tailed Students *t*-test for all experiments comparing averages of 2 groups or ANOVA (2-way with repeated measures when applicable) with Tukey, Bonferroni or Sidak post-tests (with adjustment for multiple comparisons when applicable) using GraphPad Prism software. Chi-squared tests were used to analyze genotype frequency in mouse crosses.

3. Results {#sec3}
==========

3.1. Global *Sik1* knockout mice are normoglycemic on chow diet {#sec3.1}
---------------------------------------------------------------

To characterize the functions of SIK1 in individual tissues in glucose metabolism, we created conditional SIK1 knockout mice by flanking the exons encoding the *Sik1* kinase domain (exons 2--7) with *loxP* sites ([Figure 1](#fig1){ref-type="fig"}A). We deleted *Sik1* in all tissues using a germline Cre driver (*Gdf9*) [@bib23] and recovered fewer homozygous *Sik1* knockout animals than expected, indicating a low rate of embryonic lethality that was more pronounced in males ([Supplementary Table T2](#appsec2){ref-type="sec"}). Knockout animals were viable but displayed a defect in anabolic growth after weaning (8 week old males, WT 21.5 ± 1.35 gm; SIK1-KO 16.8 ± 1.72 gm, *p* \< 0.001, *n* = 13--14 per genotype), which was also observed in an independent global SIK1 knockout line [@bib16]. Full-length *Sik1* mRNA was absent from liver tissue of global knockout mice when analyzed with PCR primers matching the deleted region of the gene (exons 3--5, [Figure 1](#fig1){ref-type="fig"}B). PCR primers recognizing the intact 3′UTR of the gene (exon 14) amplified a partial *Sik1* mRNA ([Figure 1](#fig1){ref-type="fig"}B) that is a splice product from exon 1 to exon 8 (not shown). This truncated mRNA contains an in-frame ATG in exon 8 and is predicted to encode a truncated SIK1 protein (58 kDa) lacking the catalytic domain. Full-length SIK1 protein was absent in knockout hepatocytes ([Figure 1](#fig1){ref-type="fig"}C), and we did not detect a truncated protein in primary hepatocytes from global KO mice by direct western blotting ([Supplementary Figure S1B](#appsec2){ref-type="sec"}). Interestingly, in primary hepatocytes, the phosphorylation state of CRTC2 was not affected by *Sik1* deletion ([Figure 1](#fig1){ref-type="fig"}C). We did not detect an increase in SIK2 protein in SIK1-KO hepatocytes, nor did we observe increased *Sik2* or *Sik3* mRNA in SIK1-KO liver tissue ([Supplementary Figure S1C,D](#appsec2){ref-type="sec"}), although this does not rule out functional compensation.

We tested the hypothesis that in SIK1 knockout mice de-repression of CRTC2/CREB activity would lead to hyperglycemia and glucose intolerance. Surprisingly, global SIK1 knockout animals were normoglycemic, with slightly lower blood glucose than WT control animals in the *ad libitum* fed state and unaltered blood glucose in the fasted state ([Figure 1](#fig1){ref-type="fig"}D). Hepatic expression of rate-limiting gluconeogenic genes *Pepck* and *G6pase* paralleled the blood glucose levels, with significantly reduced expression in *ad libitum* fed SIK1-KO animals and comparable amounts of *Pepck* and *G6pase* mRNA after fasting ([Figure 1](#fig1){ref-type="fig"}E). Glucose tolerance on chow diet was also unaffected by global *Sik1* deletion ([Figure 1](#fig1){ref-type="fig"}F). We hypothesized that SIK1 limits fasting gluconeogenic gene expression in liver via inhibitory phosphorylation of CRTC2 [@bib4], [@bib11] or the class II histone deacetylase HDAC4 [@bib17], [@bib24], [@bib25], which co-activate CREB and FOXO1, respectively. Both CRTC2 and HDAC4 were normally phosphorylated in *ad libitum* fed SIK1-KO liver and appropriately dephosphorylated after overnight fasting ([Figure 1](#fig1){ref-type="fig"}G). Together these data indicate that compensation by other AMPK-related kinases is sufficient to maintain normal CRTC and HDAC phosphorylation in liver, in agreement with recent reports of other SIK family knockout mice [@bib26], [@bib27], [@bib16], [@bib28].

To determine if lower *ad libitum* glucose levels in SIK1-KO mice were a result of enhanced insulin whole body sensitivity, we performed insulin tolerance tests. SIK1-WT and global SIK1-KO animals had comparable insulin sensitivity ([Figure 1](#fig1){ref-type="fig"}H) and hepatic AKT activation following a bolus insulin injection, with slightly reduced phosphorylation on AKT(T308) in the knockout liver ([Supplementary Figure S1E,F](#appsec2){ref-type="sec"}). Mild hypoglycemia in chow fed SIK1-KO animals might also be due to enhanced insulin secretion [@bib16]. In contrast to the findings of Kim et al., plasma insulin levels were unaltered in our global SIK1-knockout mouse line on chow diet ([Supplementary Figure S2A](#appsec2){ref-type="sec"}). Similarly, hepatic cholesterol, glycogen and triglycerides as well as plasma free fatty acids were unaffected in SIK1-KO mice ([Supplementary Figure S2B--E](#appsec2){ref-type="sec"}). We conclude that global deletion of the *Sik1* catalytic domain does not affect glucose homeostasis on normal chow diet.

3.2. Global SIK1-KO mice have heightened insulin sensitivity on high-fat diet {#sec3.2}
-----------------------------------------------------------------------------

CREB/CRTC2 activity in liver becomes unrestrained in obese *db/db* mice [@bib5], and *Sik1* mRNA consequently increases [@bib15]. Despite accumulation, SIK1 does not inhibit CREB/CRTC activity in the livers of genetically obese mice, either because SIK1 is not required for CRTC2 regulation in states of obesity or because *O*-glycosylation of CRTC2 on SIK consensus phosphorylation sites in obese mice blocks phosphorylation by SIKs [@bib8]. To genetically interrogate the impact of *Sik1* on glucose metabolism in obesity, we challenged SIK1-KO mice with 60% high fat diet (HFD) for up to 20 weeks. SIK1-KO mice maintained lower body weight that WT controls throughout the experiment, but weight gain as percent of initial weight was similar ([Supplementary Figure S3A,B](#appsec2){ref-type="sec"}). Moreover, SIK1-KO and WT mice had comparable fat and lean mass as well as proportions of organs, including fat pads ([Supplementary Figure S3C,D](#appsec2){ref-type="sec"}). We anticipated that SIK1-KO animals would have exacerbated glucose intolerance on HFD. Remarkably, SIK1-KO mice were protected from HFD-induced glucose intolerance, with reduced total glucose excursion during glucose tolerance tests ([Figure 2](#fig2){ref-type="fig"}A,B). This is partly explained by increased circulating insulin in response to glucose bolus in SIK-KO mice under HFD conditions ([Figure 2](#fig2){ref-type="fig"}C), consistent with recent findings that *Sik1*-deficient beta cells have enhanced glucose-stimulated insulin secretion [@bib16]. However, we reasoned that enhanced beta cell function is not sufficient to explain the improved glucose tolerance, as SIK1-KO mice also have heightened insulin sensitivity judged by insulin tolerance test ([Figure 2](#fig2){ref-type="fig"}D, [Supplementary Figure S3E](#appsec2){ref-type="sec"}). Surprisingly, 15 min after insulin injection, AKT phosphorylation on both Thr308 and Ser473 was comparable in skeletal muscle ([Figure 2](#fig2){ref-type="fig"}E, [Supplementary Figure S3F](#appsec2){ref-type="sec"}) and liver ([Supplementary Figure S3G,H](#appsec2){ref-type="sec"}) of WT and SIK1-KO mice. Neither of the key endogenous insulin-sensitizing hormones, adiponectin or FGF-21, was induced in SIK1-KO animals to a pharmacologically significant level ([Supplementary Table T3, Supplementary Figure S3I](#appsec2){ref-type="sec"}), although plasma FGF21 was elevated in fasted SIK1-KO mice fed high fat diet.

To obtain a more accurate measure of glucose turnover and insulin sensitivity in these animals, we used tracer techniques and hyperinsulinemic-euglycemic clamps. We found that basal glucose production (EndoR~a~) was not significantly increased in fasted SIK1-KO animals versus controls ([Figure 2](#fig2){ref-type="fig"}F), consistent with pyruvate tolerance tests and unchanged gluconeogenic gene expression ([Supplementary Figure S3J--L](#appsec2){ref-type="sec"}). In response to hyperinsulinemia, we found that the glucose infusion rate required to achieve and maintain euglycemia in SIK1-KO animals was higher than in controls ([Figure 2](#fig2){ref-type="fig"}G, [Supplementary Figure S3M,N](#appsec2){ref-type="sec"}), indicating improved whole-body insulin sensitivity in agreement with ITT results (see [Figure 2](#fig2){ref-type="fig"}D). Utilizing a glucose analog tracer, we observed elevated insulin-stimulated glucose uptake in the skeletal muscles of HFD-fed SIK1-KO animals ([Figure 2](#fig2){ref-type="fig"}H). These data show that global SIK1 knockout does not exacerbate HFD-induced hyperglycemia. On the contrary, SIK1-KO mice have improved glucose tolerance due in part to enhanced peripheral insulin sensitivity and skeletal muscle glucose disposal.

3.3. SIK1 synthesis and degradation are highly regulated in hepatocytes {#sec3.3}
-----------------------------------------------------------------------

Our results in global SIK1 knockout animals prompted two major questions: 1) why is gluconeogenesis unaffected and 2) how and where does SIK1 promote insulin resistance in obesity? We reasoned that lack of increased gluconeogenesis in global SIK1 knockout mice could result from A) functional compensation by other AMPK-related kinases, B) the impact of disrupted growth pathways on systemic metabolism, or C) an effect of *Sik1* deletion in extra-hepatic tissues that could mask liver effects. To explore these hypotheses, we first investigated SIK1 regulation and function in isolated mouse hepatocytes. SIK1 was highly induced in hepatocytes in response to glucagon [@bib4], peaking from 1 h (mRNA) to 3 h (protein) ([Figure 3](#fig3){ref-type="fig"}A,B; [Supplementary Figure S4A](#appsec2){ref-type="sec"}). Notably, neither *Sik2* nor *Sik3* mRNA was induced by glucagon in a similar fashion ([Supplementary Figure S4B](#appsec2){ref-type="sec"}). Newly translated SIK1 is thought to contribute to CRTC2 inhibition after feeding, although it is striking that at peak SIK1 protein expression, CRTC2 is maximally de-phosphorylated ([Figure 3](#fig3){ref-type="fig"}B, lane 2). This is most likely because sustained cAMP signaling causes direct PKA phosphorylation and nuclear export of SIKs, blocking phosphorylation of nuclear SIK substrates [@bib29], [@bib18]. When the priming glucagon stimulus was washed away and hepatocytes were chased in control medium, SIK1 protein was dephosphorylated ([Figure 3](#fig3){ref-type="fig"}B, lanes 3--7) and presumably entered the nucleus where it phosphorylates CRTCs. Indeed, CRTC2 was re-phosphorylated over the same time course ([Figure 3](#fig3){ref-type="fig"}B). We noticed that SIK1 is very unstable in hepatocytes, with an estimated half-life of 30 min, and that the proteasome inhibitor MG-132 stabilized SIK1 protein ([Figure 3](#fig3){ref-type="fig"}C,D). Thus, SIK1 is induced in hepatocytes but only has approximately 30--60 min to act on CRTCs or other substrates before the protein is degraded. Although SIK2 does not accumulate in response to glucagon, SIK2 protein was also somewhat destabilized after glucagon removal ([Supplementary Figure S4C, D](#appsec2){ref-type="sec"}), indicating that these two kinases may be degraded by a common molecular mechanism in hepatocytes.

To test the contribution of newly synthesized SIK1 to CRTC2 re-phosphorylation, we performed similar glucagon priming and chase assays in hepatocytes from WT and SIK1-KO mice. As expected, CRTC2 was dephosphorylated in both WT and SIK1-KO hepatocytes after glucagon treatment ([Figure 3](#fig3){ref-type="fig"}E). During the chase period, CRTC2 re-phosphorylation was delayed in cells genetically deficient for *Sik1*, although CRTC2 phosphorylation was eventually fully restored in cells of both genotypes ([Figure 3](#fig3){ref-type="fig"}E). In keeping with the proposed model of SIK1 action in hepatocytes, SIK1-KO hepatocytes also had stronger transcriptional responses to glucagon ([Figure 3](#fig3){ref-type="fig"}F) and synthesized more glucose *ex vivo* than control hepatocytes ([Figure 3](#fig3){ref-type="fig"}G). Therefore, newly synthesized SIK1 contributes to inactivation of CRTC2 and control of glucose synthesis *ex vivo.* However, other CRTC2 kinases such as SIK2, SIK3 or AMPK isoforms are sufficient to maintain CRTC2 phosphorylation in resting hepatocytes or at longer intervals after cessation of glucagon signaling. There is little SIK1 expressed in resting hepatocytes ([Figure 3](#fig3){ref-type="fig"}) or *ad libitum* fed liver [@bib4], and it is yet unknown what specific role SIK1 may have in the fed state.

SIK1-KO animals have a small body size that could influence metabolism of the isolated hepatocytes. These animals also express a partial *Sik1* mRNA ([Figure 1](#fig1){ref-type="fig"}B) predicted to encode a catalytically inactive truncated protein. We therefore acutely inhibited *Sik1* expression in hepatocytes by two additional methods. Transfection of a *Sik1*-selective siRNA that targets the remaining 3′ end of the mRNA resulted in higher glucose output after 6 h glucagon treatment, but not in un-stimulated cells ([Supplementary Figure S5A,B](#appsec2){ref-type="sec"}). We also isolated hepatocytes from *Sik1*^*fl/fl*^ animals and treated the cells successively with adenovirus encoding GFP or Cre recombinase and control siRNA or the same si-SIK1. Cre-mediated *Sik1* deletion *ex vivo* also potentiated glucagon-stimulated glucose output, which was not further enhanced by transfection with si-SIK1 ([Supplementary Figure S5C,D](#appsec2){ref-type="sec"}). Together these data show that eliminating SIK1 expression in primary hepatocytes promotes glucagon-stimulated glucose production *ex vivo* and confirm that the remaining truncated *Sik1* mRNA does not contribute to glucose regulation in hepatocytes. Interestingly, acute inhibition of *Sik1* expression in hepatocytes does not result in increased basal glucose production as we observed in hepatocytes from global SIK1-KO mice ([Figure 3](#fig3){ref-type="fig"}G), indicating that either longer-term deletion of *Sik1* stimulates autophagy [@bib30] or amino acid utilization for gluconeogenesis [@bib31] or that the endocrine environment in the global SIK1-KO animals might influence hepatocyte metabolism even after isolation.

3.4. Liver-specific *Sik1* knockout does not affect glucose metabolism {#sec3.4}
----------------------------------------------------------------------

Having observed increased glucose output and gluconeogenesis in isolated hepatocytes with *Sik1* knockout or knock-down, we reasoned that *Sik1* deletion in an extra-hepatic tissue might mask these effects *in vivo* in global SIK1-KO mice. We therefore acutely deleted *Sik1* in hepatocytes of adult *Sik1*^*fl/fl*^ mice by injecting adeno-associated virus (AAV) that expresses *Cre* from the hepatocyte-specific thyroxine-binding globulin (TBG) promoter [@bib32]. Compared with controls, *Sik1*^*fl/fl*^ mice infected with AAV-TBG-Cre (SIK1-AAV-LKO mice) had 75% *Sik1* deletion in whole liver tissue ([Figure 4](#fig4){ref-type="fig"}A, [Supplementary Figure S6A](#appsec2){ref-type="sec"}) that did not occur in other tissues ([Supplementary Figure S6B](#appsec2){ref-type="sec"}). In hepatocytes isolated from AAV infected animals, neither full-length SIK1 protein nor *Sik1* mRNA was detectable ([Figure 4](#fig4){ref-type="fig"}B, [Supplementary Figure S6C](#appsec2){ref-type="sec"}). Similar to hepatocytes isolated from SIK1-KO mice, hepatocytes from SIK1-AAV-LKO mice exhibited a stronger gluconeogenic transcriptional response to glucagon *ex vivo* ([Figure 4](#fig4){ref-type="fig"}C, [Supplementary Figure S6D](#appsec2){ref-type="sec"}). Homozygous *Sik1* floxed animals show a mild (7%) reduction in body weight ([Supplementary Figure S6E](#appsec2){ref-type="sec"}), in contrast to the ∼25% reduction in body weight of homozygous global SIK1-KO animals. AAV encoding *Cre* or *Gfp* had no further effect, indicating that the floxed allele has reduced function to promote anabolic growth in a different tissue. Unlike the mild hypoglycemia observed in global SIK1-KO mice, chow-fed SIK1-AAV-LKO animals had identical blood glucose under both *ad libitum* fed and fasted conditions ([Figure 4](#fig4){ref-type="fig"}D) as well as normal glucose tolerance ([Figure 4](#fig4){ref-type="fig"}E) compared with Cre control animals. Consistently, we observed no difference in hepatic *Pepck* mRNA ([Figure 4](#fig4){ref-type="fig"}F) or CRTC2 phosphorylation in liver of mice lacking *Sik1* specifically in hepatocytes ([Figure 4](#fig4){ref-type="fig"}G). We performed the same experiments in *Sik1* floxed mice crossed to *Alb-Cre* transgenic mice [@bib33] to induce chronic postnatal hepatocyte specific *Sik1* deletion. As expected, *Sik1* was only knocked out in liver, with 90% mRNA reduction in hepatocytes isolated from SIK1-LKO mice ([Supplementary Figure S7A--C](#appsec2){ref-type="sec"}). Just as in AAV-LKO mice, SIK1-LKO animals showed no alteration in fasting or fed blood glucose levels or glucose tolerance on chow diet ([Supplementary Figure S7D,E](#appsec2){ref-type="sec"}). We conclude that hepatocyte SIK1 is not required *in vivo* for regulation of CREB/CRTC2 activity or glucose homeostasis on chow diet.

Hepatic CRTC2/CREB has been shown to contribute to excessive gluconeogenesis in obese rodents [@bib8], [@bib9], [@bib6]. Although we found that basal glucose production in HFD-fed global SIK1-knockout mice was comparable to control mice, we tested glucose metabolism in HFD-fed SIK1-LKO animals to rule out impact of another tissue on the liver in the global SIK1-KO model. Liver-specific SIK1-LKO mice (*Alb-Cre*) fed HFD had comparable body weight and food intake to littermate control mice ([Supplementary Figure S8A,B](#appsec2){ref-type="sec"}). Interestingly, obese SIK1-LKO animals showed neither worsened nor improved glucose or insulin tolerance compared to littermate Cre controls ([Supplementary Figure S8C--E](#appsec2){ref-type="sec"}). These data provide the first rigorous genetic evidence that hepatic SIK1 is dispensable for regulation of glucose metabolism on chow or HFD and that the observed increase of *Sik1* in *db/db* livers, likely a consequence of activated CREB activity, does not serve an important modulatory role on glucose metabolism. Moreover, the data clearly indicate that loss of *Sik1* in hepatocytes does not contribute to the improved insulin sensitivity on high fat diet that is observed in global KO mice.

3.5. Skeletal muscle SIK1 promotes insulin resistance in obesity {#sec3.5}
----------------------------------------------------------------

We have shown that despite the fact that primary hepatocytes lacking SIK1 produce more glucose, mice lacking SIK1 are not hyperglycemic. Instead, global SIK1-KO mice fed high fat diet have markedly enhanced peripheral insulin sensitivity and increased insulin-stimulated skeletal muscle glucose disposal (see [Figure 2](#fig2){ref-type="fig"}, [Supplementary Figure S3](#appsec2){ref-type="sec"}). *Sik1* mRNA has been shown to increase in skeletal muscle, liver and adipose tissue of obese *db/db* mice [@bib15]. Similarly, we found that *Sik1* mRNA increases three-fold in skeletal muscle after 12 weeks of 60% HFD feeding in mice ([Figure 5](#fig5){ref-type="fig"}A), suggesting that SIK1 might contribute to insulin resistance in obesity by a muscle autonomous mechanism. To test this hypothesis, we crossed *Myf5*^*Cre/+*^ knock-in animals [@bib34] with *Sik1* floxed mice to efficiently delete the kinase domain of *Sik1* in the developing myotome. *Myf5-Cre* deleted exons encoding the *Sik1* catalytic domain in skeletal muscle and brown adipose tissue but not other adult tissues we tested, including heart and pancreas ([Supplementary Figure S9A](#appsec2){ref-type="sec"}). SIK1-MKO mice had grossly normal muscle structure and did not show evidence of degeneration in histological sections (not shown). *Sik1* mRNA was almost undetectable in both skeletal muscle and BAT of SIK1-MKO mice ([Figure 5](#fig5){ref-type="fig"}B, [Supplementary Figure S9B](#appsec2){ref-type="sec"}). Deletion of *Sik1* in BAT could confound analysis of skeletal muscle *Sik1* action in this mouse line. To circumvent this, we crossed *Sik1* floxed animals with *Adiponectin-Cre* BAC transgenic mice [@bib35] to generate fat-specific SIK1 knockout mice (SIK1-FKO). Similar to SIK1-LKO mice, SIK1-FKO mice did not display any glucose homeostasis phenotypes on either chow or HFD ([Supplementary Figure S10](#appsec2){ref-type="sec"}), indicating that adipose tissue *Sik1* does not make a major contribution to glucose metabolism in obesity. We therefore term the *Sik1*^*fl/fl*^*;Myf5*^*Cre/+*^ mice "muscle-specific" KO (SIK1-MKO) and interpret phenotypes as driven primarily by skeletal muscle *Sik1* deletion.

On chow diet, SIK1-MKO mice had normal glucose tolerance and muscle AKT2 activation in response to insulin ([Supplementary Figure S9C--E](#appsec2){ref-type="sec"}). Unlike global SIK1-KO animals, SIK1-MKO mice did not exhibit smaller body weight when compared to control animals ([Supplementary Figure S9F](#appsec2){ref-type="sec"}). In response to 60% HFD feeding, SIK1-MKO and Cre controls gained a comparable amount of weight and had similar percentages of lean and fat mass ([Supplementary Figure S9F--H](#appsec2){ref-type="sec"}). Importantly, HFD fed SIK1-MKO animals exhibited a slightly weaker insulin response to glucose than Cre controls ([Figure 5](#fig5){ref-type="fig"}C), indicating that the improvement in beta cells observed in global KO mice ([Figure 2](#fig2){ref-type="fig"}C and cit [@bib16]) does not occur in the SIK1-MKO line. In spite of this, glucose tolerance tests of HFD-fed SIK1-MKO mice exhibited a trend toward improved glucose tolerance (*p* = 0.1 for effect of genotype by ANOVA), which was significant at the late time points by individual *t*-tests ([Figure 5](#fig5){ref-type="fig"}D, [Supplementary Figure S9I](#appsec2){ref-type="sec"}). To precisely test insulin sensitivity in these animals, we performed hyperinsulinemic euglycemic clamps. Basal endogenous glucose production (EndoR~a~) was slightly reduced in SIK1-MKO animals, and insulin reduced endogenous glucose production in both genotypes ([Supplementary Figure S9](#appsec2){ref-type="sec"}J). Similar to results in global SIK1-KO mice, substantially more exogenous glucose was required to achieve and maintain euglycemia in HFD-fed SIK1-MKO mice than in control animals ([Figure 5](#fig5){ref-type="fig"}E, [Supplementary Figure S9K,L](#appsec2){ref-type="sec"}), indicating improved whole body insulin sensitivity. The glucose disposal and skeletal muscle 2-deoxyglucose uptake rates at dynamic steady state were also significantly elevated in SIK1-MKO mice ([Figure 5](#fig5){ref-type="fig"}F,G). Enhanced glucose disposal was not due to increased *Glut4*, *Glut1* or *Glut12* mRNA expression in SIK1-MKO muscle ([Supplementary Figure S9M](#appsec2){ref-type="sec"}). Surprisingly, basal and insulin-stimulated AKT2 phosphorylation in skeletal muscle was also not significantly induced in obese SIK1-MKO versus control animals ([Figure 5](#fig5){ref-type="fig"}H and [Supplementary Figure S9N](#appsec2){ref-type="sec"}). Altogether these data demonstrate that *Sik1* is upregulated in skeletal muscle of mice with diet-induced obesity, where it contributes to impaired insulin-stimulated glucose uptake.

4. Discussion {#sec4}
=============

During fasting CREB and its co-activator CRTC2 stimulate gluconeogenic gene transcription in hepatocytes and thus form a crucial regulatory node in the hepatic response to fasting [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]. CRTC2 is a dynamic component within this transcriptional complex due to its regulated subcellular localization controlled by inhibitory phosphorylation by several kinases including SIK1-3, MARK2 and AMPK isoforms. Of particular interest is SIK1, which is a CREB transcriptional target poised to act as a feedback inhibitor of CREB activity and limit the response to fasting [@bib4]. In addition to its proposed role as a CREB/CRTC2 inhibitor in liver, SIK1 couples the CREB and MEF2 pathways in muscle, promoting survival in adult muscle [@bib17] and differentiation of muscle progenitor cells [@bib18]. *Sik1* expression has also been shown to increase in skeletal muscle of obese *db/db* [@bib15], HFD fed ([Figure 5](#fig5){ref-type="fig"}A), injured [@bib20], and exercise trained mice [@bib19]. SIK1 is also expressed in other tissues, such as vascular smooth muscle where it regulates Na/K-ATPase activity and blood pressure [@bib36]. To test the hypothesis that SIK1 represses hepatic glucose output and to potentially identify novel functions of SIK1 in other tissues, we created conditional *Sik1* knockout mice and tested glucose metabolism phenotypes in global SIK1-KO as well as selective liver-, adipose- or skeletal muscle SIK1-knockout mice.

Mice lacking the catalytic domain of SIK1 in all tissues are viable, but display a reduction in post-weaning anabolic growth, which could be a manifestation of a complex endocrine phenotype in these animals that also impacts hepatocyte glucose production *ex vivo* (see [Figure 3](#fig3){ref-type="fig"}). In future studies, it would be useful to employ an inducible Cre for additional analysis of phenotypes resulting from global *Sik1* deletion after development. Nonetheless, similar to a recent report in an independent SIK1 knockout line [@bib16], global KO animals are largely normoglycemic on chow diet but exhibit strikingly improved glucose tolerance on high fat diet, with increased circulating insulin after glucose challenge. In addition to this mechanism, we show for the first time that SIK1-knockout animals have profoundly increased peripheral insulin sensitivity judged by insulin tolerance test, 2-deoxyglucose uptake and hyperinsulinemic-euglycemic clamps. It is possible that this phenotype was overlooked in the prior report because clamps were not performed.

Using conditional knockout mice, we conclusively demonstrate that hepatocyte SIK1 is not required to regulate gluconeogenesis *in vivo.* These data contrast the effects of acute *Sik1* knock-down in hepatocytes (see [Figure 3](#fig3){ref-type="fig"} and [Supplementary Figure S5](#appsec2){ref-type="sec"}) and livers [@bib4], which is sufficient to de-repress CREB/CRTC2 activity and glucose production. The discrepancies between these studies could reflect the contribution of inflammation to the former studies or the method of deletion. Indeed, the *Sik1*-selective shRNA employed causes destruction of the *Sik1* transcript [@bib17], while a partial *Sik1* mRNA remains in our knockout mouse liver. However, an independent global SIK1-KO mouse also showed no obvious hyperglycemia or hyperlipidemia [@bib16], and we observed no further potentiation of glucose output when we transfected primary hepatocytes with an siRNA that would inhibit the partial mRNA expressed in our KO line. Therefore, although glucagon signaling dynamically regulates SIK1 mRNA and protein in hepatocytes by both synthesis and regulated protein degradation, and newly synthesized SIK1 contributes to CRTC2 regulation in primary hepatocytes, other CRTC kinases can functionally compensate for *Sik1* knockout *in vivo*. Our results, along with findings from global SIK2 knockout mice, SIK3 knockout hepatocytes, and combination AMPK-alpha1/alpha2 knockout mice, indicate that there is significant functional redundancy among AMPK-related kinases in liver to maintain CRTC2 and HDAC4 phosphorylation and prevent excessive glucose output that is observed in *Lkb1*-deficient hepatocytes [@bib37], [@bib38], [@bib26], [@bib27], [@bib16], [@bib28]. As LKB1 is the requisite upstream activating kinase for all AMPK-related kinases [@bib39], it is not surprising that CRTC2 and HDAC4 phosphorylation are more severely affected by *Lkb1* deletion.

Our results that skeletal muscle knockout of SIK1 specifically improves insulin sensitivity on high fat diet (compared with liver or adipose tissue SIK1-KO) have begun to reveal new and unexpected functions of this kinase that are distinct from its closely related family members SIK2 and SIK3, despite the fact that each of these kinases is capable of phosphorylating and inhibiting CRTCs and class II HDACs. *Sik3* knockout results in highly penetrant embryonic lethality due to defects in chondrocyte hypertrophy, which occurs through a SIK3-class II HDAC pathway [@bib40]. Surviving animals have complex metabolic phenotypes [@bib41], and hepatocytes from these animals exhibit the expected increase in CREB-mediated gluconeogenesis [@bib28]. Global SIK2 knockout mice have enhanced CRTC2/CREB activity in white adipocytes, which contributes to insulin resistance, hyperglycemia, and hypertriglyceridemia in that model [@bib27]. In adipocytes, SIK2 stimulates *Glut4* mRNA expression and glucose uptake [@bib42], which is apparently opposite to the overall action of SIK1 in skeletal muscle. SIK1, on the other hand promotes myogenic differentiation *in vitro* [@bib18], myofiber survival [@bib17] and blood pressure regulation [@bib36], and we now show that SIK1 promotes insulin resistance in skeletal muscle in the context of over-nutrition. In contrast to *Sik2* and *Sik3*, deletion of *Sik1* in mice improves insulin sensitivity and glucose disposal in skeletal muscle.

The molecular mechanism responsible for improved physiological insulin sensitivity in *Sik1*-deficient muscle remains elusive. It is surprising that insulin-stimulated AKT2 phosphorylation is not elevated in HFD SIK1-MKO muscles compared to controls. Although PI(3)-kinase stimulates glucose uptake in myocytes by AKT2-dependent [@bib43] and AKT2-independent mechanisms [@bib44], it seems unlikely that SIK1 alters insulin signaling to PI(3)-kinase without also affecting AKT2. The best-characterized SIK1 substrates in skeletal muscle are transcriptional regulators CRTC and class II HDACs. Loss of SIK1 would cause hyper-activation of both CRTC2 and class II HDACs, the latter resulting in MEF2 inhibition. Notably, an AMPK-HDAC-MEF2 pathway has been shown to stimulate *Glut4* mRNA expression after exercise in skeletal muscle [@bib45]. However, the phenotype of increased glucose transport in SIK1-KO muscle is opposite to the expected effect of reduced MEF2 activity, and *Glut4* mRNA is not altered in SIK1-KO muscles. Our data do not, however, rule out altered GLUT transporter trafficking in the SIK1-KO skeletal muscle. Gain of CRTC function is another intriguing possible mechanism. Indeed, transgenic overexpression of constitutively activated CRTC2 in skeletal muscle resulted in hypertrophy and improved glycogen storage [@bib19]. It is possible that increased glucose utilization could establish a steeper glucose concentration gradient across the sarcolemma, which could account for the increased glucose uptake we observe in SIK1-deficient skeletal muscle. Of note, global CRTC2 knockout mice were also shown have enhanced insulin sensitivity [@bib6], suggesting that CRTC2 gain of function may not account for improved insulin sensitivity in SIK1 knockout mice. Whether SIK1 could regulate muscle glucose uptake and utilization by direct phosphorylation of enzymes involved in glucose metabolism or by a transcriptional mechanism remains to be determined. Finally, acute knock-down of full-length *Sik1* mRNA in undifferentiated skeletal myoblasts impairs myogenic differentiation [@bib18] but skeletal muscle development appears grossly unaffected in mice lacking the catalytic domain of SIK1 either globally or in Myf5-expressing muscle progenitor cells. This could be due to either compensation by other proteins *in vivo* for loss of *Sik1* or expression of a partial SIK1 protein in skeletal myocytes that supports differentiation. We therefore do not believe that a defect in muscle development accounts for the phenotype of improved insulin sensitivity on high fat diet. In future studies, it will be important to rule this out using an inducible myofiber-selective Cre.

Our findings are significant in establishing a new role for *Sik1* in extra-hepatic tissues that is of potential clinical importance. *Sik1* transcription increases in skeletal muscle of obese animals, and genetic deletion of *Sik1* ameliorates insulin resistance on high fat diet. These findings coupled with the finding that deletion of *Sik1* in all tissues or specifically in hepatocytes has no detectable impact on hepatic gluconeogenesis, renders SIK1 a promising therapeutic target to improve peripheral insulin sensitivity in overweight or obese patients without deleterious consequences on hepatic gluconeogenesis. It will be important in future studies to identify SIK1-selective catalytic inhibitors and test their efficacy in preclinical models of type 2 diabetes as well as to delineate the molecular mechanism underlying SIK1-mediated insulin resistance in skeletal muscle.
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![**Global SIK1 knockout mice are normoglycemic**. A) Schematic of mouse *Sik1* locus with *loxP* sites shown. Cre-mediated recombination removes exons 2--7 (kinase domain). B) qPCR of *Sik1* mRNA in the deleted region (exons 3--5) or intact genomic region (exon 14), normalized to *Rpl32*, fold of WT (mean ± stdev; *n* = 5 per genotype; \*, *p* \< 0.05). C) SIK1, CRTC2 and HSP90 proteins in glgn-treated primary WT and SIK1-KO hepatocytes. Open arrowhead, phospho-CRTC2; filled arrowhead, dephosphorylated CRTC2. D) *Ad libitum* and fasting blood glucose in global SIK1-KO mice (mean ± stdev; *n* = 10 per genotype; \*, *p* *\<* 0.05 KO vs WT (*ad lib*); *\#, p* *\<* 0.05 fasted vs *ad lib* within genotype). E) Gluconeogenic gene expression in SIK1 knockout liver, *ad libitum* fed or after 16 h fasting, (mean ± stdev; *n* = 4--6 per genotype; \*, *p* *\<* 0.05 KO vs WT (*ad lib*); *\#, p* *\<* 0.05 fasted vs *ad lib* within genotype). F) GTT of wild type and SIK1-KO mice (mean ± stdev*; n* = 5--6 per genotype). G) CRTC2 and class II HDAC phosphorylation in liver tissue of SIK1-WT and SIK1-KO mice *ad libitum* fed or 16 h fasted. H) ITT of SIK1-WT and SIK1-KO mice (mean ± stdev, *n* = 5--6 per genotype).](gr1){#fig1}

![**SIK1-knockout mice are protected from insulin resistance in obesity**. A) GTT of male global SIK1-KO mice after 16--18 weeks of high fat diet feeding (mean ± stdev; *n* = 6--8 per genotype among 2 cohorts; 2-way repeated measures ANOVA *p* *\<* 0.0001; Bonferroni post-tests: \*, *p* \< 0.05; \*\*\*, *p* \< 0.001 *vs* WT at indicated time points). B) Area under curve analysis of GTT in panel A (mean ± stdev; *n* = 6--8 per genotype; \*, *p* \< 0.05). C) Plasma insulin in HFD fed male SIK1-KO mice after overnight fast and 15 min after glucose injection (mean ± stdev; *n* = 11--12 per genotype among 2 cohorts; \*, *p* \< 0.05). D) ITT of male HFD SIK1-KO mice (mean ± stdev; *n* = 4--5 per genotype; 2-way repeated measures ANOVA *p* = 0.06; Bonferroni post-test: \*\*\*, *p* \< 0.001 vs WT at indicated time points). E) Western blots of phosphorylated and total AKT in quadriceps muscle from male HFD-fed SIK1-WT and KO animals euthanized *ad libitum* or after 6 h fast and IP insulin (15 min). Each lane represents one animal (*n* = 4 per condition). See [Supplementary Figure S3F](#appsec2){ref-type="sec"} for densitometry. F) Rate of endogenous glucose appearance (EndoR~a~) in fasted HFD male SIK1-WT and SIK1-KO mice 60 min after \[3-^3^H\]-glucose tracer infusion (mean ± stdev; *n* = 4--5 per genotype). G) Glucose infusion rate (GIR) at the final time point of hyperinsulinemic euglycemic clamp in dynamic steady state (mean ± stdev; *n* = 4--5 per genotype; \*\*, *p* \< 0.01). See [Supplementary Figure S3M,N](#appsec2){ref-type="sec"} for time courses. H) Insulin-stimulated biodistribution of ^18^F-fluorodeoxyglucose in male HFD fed mice (mean ± stdev; *n* = 4--5 per genotype; \*, *p* \< 0.05 vs WT).](gr2){#fig2}

![**SIK1 is dynamically regulated and regulates CRTC2 in primary hepatocytes**. A) qPCR analysis of *Sik1* mRNA in primary mouse hepatocytes treated with glucagon (Glgn, 100 nM). Fold change of *Sik1* from untreated cells, normalized to *Gapdh* (mean ± stdev; *n* = 3; \*, *p* \< 0.05 vs untreated. B) Primary mouse hepatocytes were left untreated (lane 1) or stimulated with Glgn (100 nM) for 3 h (lanes 2--7) followed by wash and chase in normal growth medium containing cycloheximide (CHX, 50 μg/mL) for the times indicated (lanes 3--7). Open arrowhead, phospho-CRTC2; filled arrowhead, dephosphorylated CRTC2. C) SIK1 protein in primary hepatocytes treated as in panel B. In lanes 6--7, MG-132 (10 μM) was added for the final 30 min of FSK/IBMX stimulation and during the CHX chase. SIK1 and HSP90 proteins shown. D) Percent SIK1 protein normalized to HSP90 during CHX chase assays (mean % remaining ± stdev, *n* = 4; \*\*\*, *p* \< 0.001 vs CHX; \#\#, *p* \< 0.01 or \#\#\#, *p* \< 0.001 vs no chase. E) Glgn priming and CHX chase assay on WT and SIK1-KO hepatocytes as in [Figure 1](#fig1){ref-type="fig"}B. Western blots show CRTC2 (open arrowhead, phosphorylated; filled arrowhead, dephosphorylated), SIK1 and HSP90 proteins. \*, non-specific band. F) *Pepck* mRNA in SIK1-WT and SIK1-KO primary hepatocytes treated with glgn for up to 3 h. (Avg of *n* = 2 biological replicates ± stdev, fold of unstimulated of same genotype; \*\*\*, *p* *\<* 0.001 vs control within genotype; \#, *p* *\<* 0.05 or \#\#, *p* \< 0.01 KO vs WT each time point). Representative assay of 4 experiments. G) Glucose output assay of SIK1-WT and SIK1-KO primary hepatocytes incubated with pyruvate, lactate, and either glgn or vehicle (control) (mean ± stdev; *n* = 3; \*, *p* \< 0.05 glgn vs control within genotype; \#, *p* \< 0.01 KO vs WT). All panels represent *n* ≥ 3 individual experiments on hepatocytes isolated on at least two separate days.](gr3){#fig3}

![**Hepatocyte-specific SIK1 knockout mice are normoglycemic on chow diet**. A) *Sik1* mRNA (exon 14) in liver of SIK1-AAV-LKO mice or controls, normalized to *Rpl32* (mean fold of control ± SEM; *n* = 2 per genotype; \*\*, *p* = 0.01). B) Western blot of SIK1 protein in glgn-stimulated hepatocytes isolated from wild type (*Sik1*^*+/+*^) or floxed (*Sik1*^*fl/fl*^*)* animals injected with AAV-TBG-GFP or AAV-TBG-Cre. \*, non-specific band. C) *Pepck* mRNA in primary hepatocytes from an AAV infected animal (mean ± stdev; *n* *=* 3 biological replicates; \*\*, *p* \< 0.01 control vs glgn; \#\#, *p* \< 0.01 glgn GFP vs glgn Cre). D) Blood glucose in male control (*Sik1*^+/+^,AAV-Cre) and SIK1-AAV-LKO (*Sik1*^*fl/fl*^,AAV-Cre) (mean ± stdev; *n* = 12--14 per genotype; \#*p* \< 0.05 to *ad lib* of same genotype). E) GTT in male control and SIK1-AAV-LKO animals (mean ± stdev; *n* = 8--14 per genotype). F) qPCR of *Pepck* (mean ± stdev; *n* = 5 per genotype per condition) and G) western blot of CRTC2 in control and SIK1-AAV-LKO liver, *ad libitum* fed and overnight fasted (*n* = 3 animals per condition).](gr4){#fig4}

![**Skeletal muscle deletion of *Sik1* enhances insulin sensitivity in obesity**. A) Skeletal muscle *Sik1* mRNA in male mice fed chow diet or 12 weeks 60% HFD (*n* = 5--6 per genotype; \*\*\*\*, *p* \< 0.0001). B) *Sik1* mRNA in quadriceps skeletal muscle of female Cre control (*Myf5*^*Cre/+*^) and SIK1-MKO (mean ± stdev, *n* = 5 per genotype, \*\*\*\*, *p* \< 0.0001). C) Plasma insulin in male HFD fed SIK1-MKO mice, fasted (0) and 15 min after glucose injection IP (mean ± SEM, *n* = 4--5 per genotype, non-significant by 2-way RM ANOVA; \*, *p* \< 0.05 Cre:MKO by Sidak\'s multiple comparison test; \#, *p* \< 0.05 0:15 min glucose in Cre control by *t*-test). D) Glucose tolerance tests of male Cre control and SIK1-MKO fed 60% HFD for 12 weeks (mean ± SEM, n = 5--9 per genotype, *p* \< 0.05 by 2-way repeated measures ANOVA, effect of genotype *p* = 0.1, \**p* \< 0.05 at indicated time points by individual *t*-tests). E) Glucose infusion rate (GIR) and F) glucose disposal rate (GDR) at final time point of dynamic steady state in hyperinsulinemic euglycemic clamps of male Cre control and SIK1-MKO mice fed HFD for 19 weeks (mean ± stdev, *n* = 5 per genotype, \*\*\*\*, *p* \< 0.0001, \*, *p* \< 0.05 by *t*-test). See [Supplementary Figure S9K,L](#appsec2){ref-type="sec"} for time courses. G) Skeletal muscle 2-deoxyglucose uptake rate during last 45 min of hyperinsulinemic euglycemic clamps (mean ± stdev, *n* = 5 per genotype, \#, *p* = 0.05 by *t*-test). H) Western blots of AKT2 immunoprecipitates from male 12-week HFD-fed Cre control and MKO animals fasted for 6 h and/or administered insulin IP 15 min prior to euthanization. See [Supplementary Figure S9N](#appsec2){ref-type="sec"} for densitometry.](gr5){#fig5}
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